Becton Dickinson-CR Bard to divest medical device lines for FTC antitrust approval
MLex Summary: Becton, Dickinson and C.R. Bard agreed to divest two medical device product lines to settle Federal Trade Commission charges that BD's $24 billion acquisition would harm competition by combining the top...To view the full article, register now.
Already a subscriber? Click here to view full article